In addition, time-to-event analysis showed no difference in rates of serious infections between ustekinumab and placebo treatment, consistent with a published multicentre cohort of patients treated with biologics, in which ustekinumab was associated with a lower risk of serious infections compared with TNF-α antagonists and vedolizumab.16 The gene discussed is TNF; the disease is infection.